Impact of antiretroviral therapy on depression and sleep disorders in HIV patients
Autor(a) principal: | |
---|---|
Data de Publicação: | 2021 |
Outros Autores: | , , , |
Tipo de documento: | Artigo |
Idioma: | por |
Título da fonte: | Research, Society and Development |
Texto Completo: | https://rsdjournal.org/index.php/rsd/article/view/19989 |
Resumo: | Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir. |
id |
UNIFEI_18efa25272ded3b20d1c2241b82fe73f |
---|---|
oai_identifier_str |
oai:ojs.pkp.sfu.ca:article/19989 |
network_acronym_str |
UNIFEI |
network_name_str |
Research, Society and Development |
repository_id_str |
|
spelling |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patientsImpacto de la terapia antirretroviral en la depresión y los trastornos del sueño en pacientes con VIHImpacto da terapia antirretroviral na depressão e transtorno do sono em pacientes portadores de HIV Distúrbio do sonoHIVDepressãoTerapia antirretroviralEfavirenzDolutegravirAtazanavir.Sleep disordersHIVDepressionAntiretroviral therapyEfavirenzDolutegravirAtazanavir.Alteración del sueñoVIHDepresiónTerapia antirretroviralEfavirenzDolutegravirAtazanavir.Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir.La depresión y los trastornos del sueño son frecuentes en pacientes con VIH. El objetivo de este artículo es detectar los trastornos del sueño y la depresión relacionados con la terapia antirretroviral en la población adulta con VIH / SIDA. Se aplicaron las siguientes escalas: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adaptada a Brasil (ESS-Br) y Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. En la evaluación del sueño (PSQI), el uso de Dolutegravir (DTG) mostró un 58.8% de mala calidad del sueño, el Efavirenz (EFZ) fue un 38% indicativo de sueño deficiente y un 28.5% de trastorno del sueño, y el Atazanavir-ritonavir (ATV-r) con sueño de mala calidad se encontró en el 40%. La detección de cualquier tipo de trastorno del sueño no difirió estadísticamente entre el uso de EFZ o DTG (p = 0,79). En cuanto a la valoración de la somnolencia ESS-Br, detectamos alteraciones importantes del 4,7%, 17,2% y 20% en pacientes que utilizan EFZ, DTG y ATV, respectivamente. El análisis obtenido para la depresión (PHQ-9) fue: moderadamente grave (EFZ = 10%, DTG = 20,3%, ATV = 0%) y grave (EFZ = 15%, DTG = 6,2%, ATV = 0%). Este estudio mostró que las personas VIH positivas sufren alteraciones del sueño independientes del régimen de TAR, pero con mayor impacto con Efavirenz. La somnolencia diurna estuvo presente en uno de cada 5 individuos que usaban TAR. Y se descubrió que la mayor gravedad de la depresión era importante para los grupos que usaban efavirenz y dolutegravir.Depressão e alteração do sono são frequentes em pacientes portadores de HIV. O objetivo deste artigo é detectar alterações no sono e depressão relacionados a terapia antirretroviral na população adulta com HIV/aids. Aplicadas as escalas: Patient Health Questionnaire-9 (PHQ-9), Escala de Sonolência Epworth, adaptada ao Brasil (ESS-Br), e do Questionário Índice de Qualidade do Sono de Pittsburgh (PSQI). CEP: 3.319.628. Na avaliação do sono (PSQI), uso de Dolutegravir (DTG) apresentou 58,8% sono de qualidade ruim, Efavirenz (EFZ) foi 38% indicativo de sono ruim e 28,5% de distúrbio do sono, e Atazanavir/ritonavir (ATV-r) com sono de qualidade ruim encontrado em 40%. A detecção de qualquer tipo de alteração de sono não diferiu estatisticamente entre uso de EFZ ou DTG (p = 0,79). Com relação à avaliação da sonolência ESS-Br, detectamos 4,7%, 17,2% e 20% alteração importante dos pacientes em uso de EFZ, DTG e ATV, respectivamente. A análise obtida quanto a depressão (PHQ-9) foi: moderadamente grave (EFZ = 10%, DTG = 20,3%, ATV = 0%) e grave (EFZ = 15%, DTG = 6,2%, ATV = 0 %). Este estudo mostrou que indivíduos HIV positivos sofrem de distúrbios do sono independentes do regime de TARV, mas com maior impacto com o Efavirenz. A sonolência diurna estava presente em um de cada 5 indivíduos em uso de TARV. E a maior gravidade da depressão foi achado importante para os grupos em uso de Efavirenz e Dolutegravir.Research, Society and Development2021-09-12info:eu-repo/semantics/articleinfo:eu-repo/semantics/publishedVersionapplication/pdfhttps://rsdjournal.org/index.php/rsd/article/view/1998910.33448/rsd-v10i12.19989Research, Society and Development; Vol. 10 No. 12; e25101219989Research, Society and Development; Vol. 10 Núm. 12; e25101219989Research, Society and Development; v. 10 n. 12; e251012199892525-3409reponame:Research, Society and Developmentinstname:Universidade Federal de Itajubá (UNIFEI)instacron:UNIFEIporhttps://rsdjournal.org/index.php/rsd/article/view/19989/17924Copyright (c) 2021 Melissa Soares Medeiros; Liliane Nogueira Granjeiro; Yandra Mirelle Nogueira Alves; Jose Edvar di Castro Junior; Luan Victor Almeida Limahttps://creativecommons.org/licenses/by/4.0info:eu-repo/semantics/openAccessMedeiros, Melissa Soares Granjeiro, Liliane Nogueira Alves, Yandra Mirelle Nogueira Castro Junior, Jose Edvar di Lima, Luan Victor Almeida 2021-11-14T20:26:51Zoai:ojs.pkp.sfu.ca:article/19989Revistahttps://rsdjournal.org/index.php/rsd/indexPUBhttps://rsdjournal.org/index.php/rsd/oairsd.articles@gmail.com2525-34092525-3409opendoar:2024-01-17T09:39:45.576532Research, Society and Development - Universidade Federal de Itajubá (UNIFEI)false |
dc.title.none.fl_str_mv |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients Impacto de la terapia antirretroviral en la depresión y los trastornos del sueño en pacientes con VIH Impacto da terapia antirretroviral na depressão e transtorno do sono em pacientes portadores de HIV |
title |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
spellingShingle |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients Medeiros, Melissa Soares Distúrbio do sono HIV Depressão Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. Sleep disorders HIV Depression Antiretroviral therapy Efavirenz Dolutegravir Atazanavir. Alteración del sueño VIH Depresión Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. |
title_short |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
title_full |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
title_fullStr |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
title_full_unstemmed |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
title_sort |
Impact of antiretroviral therapy on depression and sleep disorders in HIV patients |
author |
Medeiros, Melissa Soares |
author_facet |
Medeiros, Melissa Soares Granjeiro, Liliane Nogueira Alves, Yandra Mirelle Nogueira Castro Junior, Jose Edvar di Lima, Luan Victor Almeida |
author_role |
author |
author2 |
Granjeiro, Liliane Nogueira Alves, Yandra Mirelle Nogueira Castro Junior, Jose Edvar di Lima, Luan Victor Almeida |
author2_role |
author author author author |
dc.contributor.author.fl_str_mv |
Medeiros, Melissa Soares Granjeiro, Liliane Nogueira Alves, Yandra Mirelle Nogueira Castro Junior, Jose Edvar di Lima, Luan Victor Almeida |
dc.subject.por.fl_str_mv |
Distúrbio do sono HIV Depressão Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. Sleep disorders HIV Depression Antiretroviral therapy Efavirenz Dolutegravir Atazanavir. Alteración del sueño VIH Depresión Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. |
topic |
Distúrbio do sono HIV Depressão Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. Sleep disorders HIV Depression Antiretroviral therapy Efavirenz Dolutegravir Atazanavir. Alteración del sueño VIH Depresión Terapia antirretroviral Efavirenz Dolutegravir Atazanavir. |
description |
Depression and sleep disorders are frequent in patients with HIV. The aim of this article is to detect sleep disorders and depression related to antiretroviral therapy in the adult population with HIV/AIDS. The following scales were applied: Patient Health Questionnaire-9 (PHQ-9), Epworth Sleepiness Scale, adapted to Brazil (ESS-Br), and the Pittsburgh Sleep Quality Index Questionnaire (PSQI). CEP: 3.319.628. In the sleep assessment (PSQI), use of Dolutegravir (DTG) showed 58.8% poor sleep quality, Efavirenz (EFZ) was 38% indicative of poor sleep and 28.5% of sleep disorder, and Atazanavir-ritonavir (ATV-r) with poor quality sleep was found in 40%. The detection of any type of sleep disorder did not differ statistically between the use of EFZ or DTG (p = 0.79). Regarding the assessment of ESS-Br sleepiness, we detected 4.7%, 17.2% and 20% important alterations in patients using EFZ, DTG and ATV, respectively. The analysis obtained for depression (PHQ-9) was moderately severe (EFZ = 10%, DTG = 20.3%, ATV = 0%) and severe (EFZ = 15%, DTG = 6.2%, ATV = 0%). This study showed that HIV-positive individuals suffer from sleep disturbances independent of the ART regimen, but with greater impact with Efavirenz. Daytime sleepiness was present in one in every 5 individuals using ART. And the greater severity of depression was found to be important for the groups using Efavirenz and Dolutegravir. |
publishDate |
2021 |
dc.date.none.fl_str_mv |
2021-09-12 |
dc.type.driver.fl_str_mv |
info:eu-repo/semantics/article info:eu-repo/semantics/publishedVersion |
format |
article |
status_str |
publishedVersion |
dc.identifier.uri.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19989 10.33448/rsd-v10i12.19989 |
url |
https://rsdjournal.org/index.php/rsd/article/view/19989 |
identifier_str_mv |
10.33448/rsd-v10i12.19989 |
dc.language.iso.fl_str_mv |
por |
language |
por |
dc.relation.none.fl_str_mv |
https://rsdjournal.org/index.php/rsd/article/view/19989/17924 |
dc.rights.driver.fl_str_mv |
https://creativecommons.org/licenses/by/4.0 info:eu-repo/semantics/openAccess |
rights_invalid_str_mv |
https://creativecommons.org/licenses/by/4.0 |
eu_rights_str_mv |
openAccess |
dc.format.none.fl_str_mv |
application/pdf |
dc.publisher.none.fl_str_mv |
Research, Society and Development |
publisher.none.fl_str_mv |
Research, Society and Development |
dc.source.none.fl_str_mv |
Research, Society and Development; Vol. 10 No. 12; e25101219989 Research, Society and Development; Vol. 10 Núm. 12; e25101219989 Research, Society and Development; v. 10 n. 12; e25101219989 2525-3409 reponame:Research, Society and Development instname:Universidade Federal de Itajubá (UNIFEI) instacron:UNIFEI |
instname_str |
Universidade Federal de Itajubá (UNIFEI) |
instacron_str |
UNIFEI |
institution |
UNIFEI |
reponame_str |
Research, Society and Development |
collection |
Research, Society and Development |
repository.name.fl_str_mv |
Research, Society and Development - Universidade Federal de Itajubá (UNIFEI) |
repository.mail.fl_str_mv |
rsd.articles@gmail.com |
_version_ |
1797052788942831616 |